CTOs on the Move

Cortexyme

www.cortexyme.com

 
Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.cortexyme.com
  • 329 Oyster Point Suite 300
    South San Francisco, CA USA 94080
  • Phone: 650.491.9638

Executives

Name Title Contact Details

Funding

Cortexyme raised $15M on 01/06/2016

Similar Companies

Asthmatx

Asthmatx is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zynerba

At Zynerba Pharmaceuticals, we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. Our mission is to improve the lives of patients battling severe health conditions including peripheral neuropathic pain, fibromyalgia, chronic cancer pain, epilepsy and osteoarthritis through these therapeutics. Our development pipeline includes patent-protected synthetic transdermal cannabinoid products, ZYN001 and ZYN002, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.

Odyssey Research Services

Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ceregene

Ceregene is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GrayBug

GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.